Idogen signs collaboration agreement for the production of cell therapy in haemophilia

REGULATORY

Idogen AB (Spotlight Stock Market: IDOGEN) announced today that the company has signed a collaboration agreement for production with the Radboud University Medical Center in the Netherlands, a university that is a global leader in the field and has 20 years of experience manufacturing cell therapy. The agreement marks a significant step in adapting and upscaling the manufacturing of the company’s cell therapy products prior to the start of clinical trials.

 

The collaboration aims to efficiently adapt Idogen’s technology platform for clinical use and to ensure appropriate manufacturing operations for the company’s tolerogenic cell therapy, which is under development for the treatment of antibodies against biological agents, organ rejection after transplantation and autoimmune diseases.

Professor Jolanda de Vries and her co-workers at Radboud University Medical Center, located in Nijmegen in the Netherlands, are global leaders in the field and have more than 20 years’ experience of conducting research and working practically with manufacturing cell therapy based on dendritic cells, mainly in oncology. Their extensive knowledge of taking a dendritic-cell-based therapy to the patient constitutes an important complement to the internal expertise built up at Idogen.

“In recent months, we have been evaluating the best way forward for manufacturing our cell therapy prior to the start of clinical trials and are now delighted to sign this collaboration agreement with the Radboud University Medical Center. This agreement offers us a cost-efficient and flexible solution. At the same time, it gives us an opportunity to combine our own established expertise in manufacturing cell based therapies with the world-leading know-how and capacity of our new partner,” says Anders Karlsson, CEO of Idogen AB.

Idogen’s research team has recently developed a patentable, enhanced cell therapy based on dendritic cells with a strong tolerance-inducing profile. The company is now working to upscale the production process and is establishing procedures for manufacturing operations. The new collaboration can facilitate initiation of clinical trials around the turn of the year 2020/21.

“Our team at Radboud University has successfully developed leading cell therapy projects for many years, and we are very pleased with the opportunity to collaborate with Idogen. Together we’ll make sure that Idogen’s dendritic cell therapy can be applied in a clinical setting, firstly in Haemophilia patients”, says Jolanda de Vries, Professor in immunology, Radboud Institute for Molecular Life Sciences, at the Radboud University Medical Center. 

 

For further information, please contact: 

Anders Karlsson, CEO, Idogen AB
Phone: +46 70 918 00 10
Email: anders.karlsson@idogen.com


This is an English version of an original Swedish press release communicated by Idogen AB. In case of interpretation issues or possible differences between the different versions, the Swedish version shall apply. This constitutes information that Idogen AB is required to publish under the EU’s Market Abuse Regulation. The information was submitted for publication through the above contact person on November 13, 2019.

 

Attached file